Sybren Meijer
Overview
Explore the profile of Sybren Meijer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
79
Citations
2094
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Coimbra A, Rimola J, Cuatrecasas M, De Hertogh G, Van Assche G, Vanslembrouck R, et al.
Clin Transl Gastroenterol
. 2022 Jul;
13(7):e00505.
PMID: 35905415
Introduction: Magnetic resonance enterography (MRE) is useful for detecting bowel strictures, whereas a number of imaging biomarkers may reflect severity of fibrosis burden in Crohn's disease (CD). This study aimed...
2.
Li S, Hoefnagel S, Read M, Meijer S, van Berge Henegouwen M, Gisbertz S, et al.
Cell Oncol (Dordr)
. 2022 Jul;
45(4):639-658.
PMID: 35902550
Purpose: Abnormalities within the Sonic Hedgehog (SHH), Bone Morphogenetic Protein (BMP) and SMAD4 signalling pathways have been associated with the malignant behavior of esophageal adenocarcinoma (EAC). We recently developed two...
3.
Klaver E, van der Wel M, Duits L, Pouw R, Seldenrijk K, Offerhaus J, et al.
J Clin Pathol
. 2020 May;
74(1):48-52.
PMID: 32467320
Aims: The histopathological diagnosis of low-grade dysplasia (LGD) in Barrett's oesophagus (BO) is associated with poor interobserver agreement and guidelines dictate expert review. To facilitate nationwide expert review in the...
4.
Volders J, Negenborn V, Haloua M, Krekel N, Jozwiak K, Meijer S, et al.
J Surg Oncol
. 2018 Feb;
117(5):1001-1008.
PMID: 29473960
Background And Objectives: To identify breast-specific factors and the role of tumor, treatment, and patient-related items in influencing patient opinion on cosmesis and satisfaction after breast-conserving therapy (BCT). Methods: Data...
5.
Volders J, Negenborn V, Spronk P, Krekel N, Schoonmade L, Meijer S, et al.
Breast Cancer Res Treat
. 2018 Jan;
168(1):13-15.
PMID: 29327297
In the original publication of the article, Table 2 was published incorrectly. The corrected Table 2 is given in this erratum. The original article has been corrected.
6.
Volders J, Negenborn V, Spronk P, Krekel N, Schoonmade L, Meijer S, et al.
Breast Cancer Res Treat
. 2017 Dec;
168(1):1-12.
PMID: 29214416
Purpose: Neoadjuvant chemotherapy (NACT) is increasingly used in breast cancer treatment. One of the main goals of NACT is to reduce the extent of local surgery of the breast and...
7.
Breast-conserving therapy for breast cancer: Cosmetic results and options for delayed reconstruction
Negenborn V, Volders J, Krekel N, Haloua M, Bouman M, Buncamper M, et al.
J Plast Reconstr Aesthet Surg
. 2017 Jun;
70(10):1336-1344.
PMID: 28610896
Objectives: Optimisation of the cosmetic outcome after breast-conserving therapy (BCT) is important. We aimed to determine the cosmetic outcome following BCT and factors influencing this cosmesis and identify the most...
8.
Volders J, Negenborn V, Haloua M, Krekel N, Jozwiak K, Meijer S, et al.
J Surg Oncol
. 2017 Mar;
115(8):941-948.
PMID: 28334419
Introduction: Cosmetic results and quality of life (QoL) are increasingly important in the treatment of breast cancer. This study was designed to determine the relationship between QoL and both subjectively...
9.
Scholvinck D, Kunzli H, Meijer S, Seldenrijk K, van Berge Henegouwen M, Bergman J, et al.
Surg Endosc
. 2016 Jul;
30(9):4102-13.
PMID: 27357927
Background: Esophagectomy for submucosal (T1b) esophageal adenocarcinoma (EAC) is performed in order to optimize patient outcomes given the risk of concurrent lymph node metastases (LNM). However, not seldom, comorbidity precludes...
10.
Nielsen K, Scheffer H, Volders J, van der Vorst M, van Tilborg A, Comans E, et al.
World J Surg
. 2016 May;
40(8):1951-8.
PMID: 27220509
Introduction: Systemic chemotherapy is able to convert colorectal liver metastases (CRLM) that are initially unsuitable for local treatment into locally treatable disease. Surgical resection further improves survival in these patients....